Bahrein - Engels - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

yousif mahmood hussain pharmacy - glibenclamide - tablet - 5

Bangladesh - Engels - DGDA (Directorate General of Drug Administration)

synovia pharma plc. - glibenclamide - tablet - 5 mg

Saoedi-Arabië - Engels - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi-aventis france, france - glibenclamide - tablet - 5 mg

Australië - Engels - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - glibenclamide -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide red; iron oxide yellow - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 3.125 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide red - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Ierland - Engels - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - glibenclamide - tablets - 2.5 milligram

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - glibenclamide 2.5mg - tablet - 2.5 mg - active: glibenclamide 2.5mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch purified talc